Systemic administration of an HIV-1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization

Mucosal Immunology

Volumn 10, Issue 1, 2017, Pages 228-237

  Fouda, G G ^a   Eudailey, J ^a   Kunz, E L ^a   Amos, J D ^a   Liebl, B E ^a   Himes, J ^a   Boakye Agyeman, F ^a   Beck, K ^a   Michaels, A J ^b   Cohen Wolkowiez, M ^a   Haynes, B F ^a   Reimann, K A ^b   Permar, S R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY B12 DIMERIC IMMUNOGLOBULIN A; NEUTRALIZING ANTIBODY B12 IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY B12 MONOMERIC IMMUNOGLOBULIN A; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; SECRETORY IMMUNOGLOBULIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BODILY SECRETIONS; BREAST MILK; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGLOBULIN BLOOD LEVEL; LACTATION; NONHUMAN; PASSIVE IMMUNIZATION; RECTAL SECRETION; RHESUS MONKEY; SALIVA ANALYSIS; SALIVATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VAGINAL SECRETION; VIRUS NEUTRALIZATION; ANIMAL; BLOOD; BREAST FEEDING; DIMERIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MUCOSA; SALIVA;

ANIMALS; ANTIBODIES, NEUTRALIZING; BODILY SECRETIONS; BREAST FEEDING; DIMERIZATION; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; MACACA MULATTA; MILK, HUMAN; MUCOUS MEMBRANE; SALIVA;

EID: 85011088509     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2016.32     Document Type: Article

References (46)

1. UNAIDS. 2014 Progress report on the global plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive.
2. Bork, K.A. et al. Morbidity in relation to feeding mode in African HIVexposed, uninfected infants during the first 6 mo of life: The Kesho Bora study. Am. J. Clin. Nutr. 100, 1559-1568 (2014).
3. Fowler, M.G. et al. Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trial. J. Acquir. Immune Defic. Syndr. 65, 366-374 (2014).
4. Kesho Bora Study Group, de Vincenzi, I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect. Dis. 11, 171-180 (2011).
5. Thomas, T.K. et al. Triple-antiretroviral prophylaxis to prevent mother-tochild HIV transmission through breastfeeding\-The Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med. 8, e1001015 (2011).
6. Phillips, T., Thebus, E., Bekker, L.G., McIntyre, J., Abrams, E.J. &Myer, L. Disengagement of HIV-positive pregnant and postpartum women from antiretroviral therapy services: a cohort study. J. Int. AIDS Soc. 17, 19242 (2014).
7. Ngoma, M.S. et al. Efficacy of WHO recommendation for continued breastfeeding and maternal cART for prevention of perinatal and postnatal HIV transmission in Zambia. J Int AIDS Soc 18, 19352 (2015).
8. Ngarina, M. et al. Virologic and immunologic failure, drug resistance and mortality during the first 24 months postpartum among HIV-infected women initiated on antiretroviral therapy for life in the Mitra plus Study, Dar es Salaam, Tanzania. BMC Infect. Dis. 15, 175 (2015).
9. Rousseau, C.M. et al. Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission. J. Infect. Dis. 190, 1880-1888 (2004).
10. Semba, R.D. et al. Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J. Infect. Dis. 180, 93-98 (1999).
11. Koulinska, I.N. et al. Transmission of cell-free and cell-associated HIV-1 through breast-feeding. J. Acquir. Immune Defic. Syndr. 41, 93-99 (2006).
12. Slyker, J.A. et al. Incidence and correlates of HIV-1 RNA detection in the breast milk of women receiving HAART for the prevention of HIV-1 transmission. PLoS One 7, e29777 (2012).
13. Lehman, D.A. et al. HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission. AIDS 22, 1475-1485 (2008).
14. Larson, B.L.,Heary,H.L. Jr. &Devery, J.E. Immunoglobulin production and transport by the mammary gland. J. Dairy Sci. 63, 665-671 (1980).
15. Fouda, G.G. et al. HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies. J. Virol. 85, 9555-9567 (2011).
16. Van de Perre, P., Hitimana, D.G. &Lepage, P. Human immunodeficiency virus antibodies of IgG, IgA, and IgM subclasses in milk of seropositive mothers. J. Pediatr. 113, 1039-1041 (1988).
17. Mabuka, J., Nduati, R., Odem-Davis, K., Peterson, D. &Overbaugh, J. HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog. 8, e1002739 (2012).
18. Stoddart, C.A. et al. Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice. Virology 462-463, 115-125 (2014).
19. Klein, F et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492, 118-122 (2012).
20. Horwitz, J.A. et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc. Natl. Acad. Sci. USA 110, 16538-16543 (2013).
21. Diskin, R. et al. Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. J. Exp. Med. 210, 1235-1249 (2013).
22. Halper-Stromberg, A. et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158, 989-999 (2014).
23. Permar, S.R. et al. Potent simian immunodeficiency virus-specific cellular immune responses in the breast milk of simian immunodeficiency virus-infected, lactating rhesus monkeys. J. Immunol. 181, 3643-3650 (2008).
24. Ko, S.Y. et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514, 642-645 (2014).
25. Fouda, G.G. et al. Tenascin-C is an innate broad-spectrum, HIV-1-neutralizing protein in breast milk. Proc. Natl. Acad. Sci. USA 110, 18220-18225 (2013).
26. Milligan, C. &Overbaugh, J. The role of cell-associated virus in motherto-child HIV transmission. J. Infect. Dis. 210, S631-S640 (2014).
27. Van de Perre, P. et al. HIV-1 reservoirs in breast milk and challenges to elimination of breast-feeding transmission of HIV-1. Sci. Transl. Med. 4, 143sr143 (2012).
28. Whaley, K.J. &Mayer, K.H. Strategies for preventing mucosal cellassociated HIV transmission. J Infect Dis 210, S674-S680 (2014).
29. Barouch, D.H. et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224-228 (2013).
30. Caskey,Met al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487-491 (2015).
31. Correia, I.R. Stability of IgG isotypes in serum. MAbs 2, 221-232 (2010).
32. Hladik, F. &Hope, T.J. HIV infection of the genital mucosa in women. Curr. HIV/AIDS Rep. 6, 20-28 (2009).
33. Haynes, B.F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275-1286 (2012).
34. Hur, E.M. et al. Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice. Blood 120, 4571-4582 (2012).
35. Watkins, J.D. et al. Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS 27, F13-F20 (2013).
36. Renegar, K.B., Small, P.A. Jr., Boykins, L.G. &Wright, P.F. Role of IgA versus IgG in the control of influenza viral infection in themurine respiratory tract. J. Immunol. 173, 1978-1986 (2004).
37. Alvarez, N. et al. Passive administration of purified secretory IgA from human colostrum induces protection against Mycobacterium tuberculosis in a murine model of progressive pulmonary infection. BMC Immunol. 14, S3 (2013).
38. Corthesy, B. Recombinant secretory immunoglobulin A in passive immunotherapy: linking immunology and biotechnology. Curr. Pharm. Biotechnol. 4, 51-67 (2003).
39. Carbonare, C.B., Carbonare, S.B. &Carneiro-Sampaio, M.M. Secretory immunoglobulin A obtained from pooled human colostrum and milk for oral passive immunization. Pediatr. Allergy Immunol. 16, 574-581 (2005).
40. Palmer,D.S. et al. Screening of Canadian Blood Services donors for severe immunoglobulin A deficiency. Transfusion 50, 1524-1531 (2010).
41. Rachid, R., Castells, M., Cunningham-Rundles, C. &Bonilla, F.A. Association of anti-IgA antibodies with adverse reactions to gamma-globulin infusion. J. Allergy Clin. Immunol. 128, 228-230.e221 (2011).
42. Burton, D.R., Barbas, C.F. 3rd, Persson, M.A., Koenig, S., Chanock, R.M. &Lerner, R.A. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. USA 88, 10134-10137 (1991).
43. Rogers, K.A., Jayashankar, L., Scinicariello, F. &Attanasio, R. Nonhuman primate IgA: genetic heterogeneity and interactions with CD89. J. Immunol. 180, 4816-4824 (2008).
44. Kozlowski, P.A., Lynch, R.M., Patterson, R.R., Cu-Uvin, S., Flanigan, T.P. &Neutra,M.R. Modified wick method using Weck-Cel sponges for collection of human rectal secretions and analysis of mucosal HIVantibody. J. Acquir. Immune Defic. Syndr. 24, 297-309 (2000).
45. Montefiori, D.C. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol. Biol. 485, 395-405 (2009).
46. Seaman, M.S. et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84, 1439-1452 (2010).